WuXi AppTec highlights 72.7 percent growth in small-molecule revenue

WuXi AppTec highlighted strong growth in its small-molecule business, with interim-report revenue rising 72.7 percent year over year to RMB 14.99 billion.

WuXi AppTec highlighted growth in its small-molecule development and manufacturing business in a company-published article dated September 15, 2026. Revenue from the business rose 72.7 percent year over year to RMB 14.99 billion, according to the company’s 2026 interim report. WuXi AppTec said its small-molecule pipeline reached 3,731 molecules.

Pipeline expansion

The company said 699 molecules were added during the six-month period, including 155 converted from in-house research projects. It also reported 15 new commercial and Phase III programs. The article identified WuXi STA as the small-molecule business within WuXi AppTec’s chemistry operations, providing services from active pharmaceutical ingredients to drug products. The company’s publication also said WuXi STA has supported the launch of more than 70 new drugs since 2017.

Full-year outlook

WuXi AppTec’s investor-relations page lists a company update titled “WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers’ Products and CRDMO Model.” WuXi AppTec’s investor-relations page presents the update alongside the company’s other investor communications.